EUVIMEDEUVIMED entdecken
Crossref

How I Diagnose Rosai-Dorfman Disease

Aishwarya Ravindran iD, Karen L Rech

American Journal of Clinical Pathology · 05.07.2023 · 160 (1) · 1-10

DOI: 10.1093/ajcp/aqad047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 11.05.2023. Verfasst von Aishwarya Ravindran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Division of Laboratory Medicine-Hematopathology, University of Alabama at Birmingham, Birmingham, AL, US. Hauptthemen laut MEDLINE: Histiocytosis, Sinus, Erdheim-Chester Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Rosai-Dorfman disease (RDD) is one of 3 major types of histiocytosis, along with Erdheim-Chester disease and Langerhans cell histiocytosis. While historically, RDD was considered a benign self-limited condition, current data show MAPK/ERK pathway mutations in 30% to 50% of cases, indicative of a clonal process. Rosai-Dorfman disease was incorporated as a histiocytic neoplasm in the fifth edition of the World Health Organization classification of hematopoietic tumors and the International Consensus Classification.

Methods

We discuss the diagnosis of RDD using 2 illustrative cases, interpretative challenges, and a diagnostic algorithm.

Results

Rosai-Dorfman disease involves nodal and extranodal sites, including skin, sinuses, salivary gland, orbit, central nervous system, kidney, and bone. In a subset, RDD can coexist with other neoplasms (lymphomas, other histiocytosis) or autoimmune disease. Morphologically, RDD histiocytes are characterized by enlarged round to oval nuclei, distinct nucleoli, and voluminous cytoplasm with engulfment of inflammatory cells (emperipolesis). By immunohistochemistry, they express CD68, CD163 (majority), S100, OCT2, and cyclin D1. Appropriate use of ancillary studies is important to support the diagnosis of RDD while excluding other histiocytic neoplasms and reactive histiocytic proliferations.

Conclusions

Management of RDD is dependent on the extent of organ involvement and clinical symptoms. In patients who require therapy, next-generation sequencing is recommended to identify MAPK/ERK pathway mutations for targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytosis, SinusErdheim-Chester DiseaseHematologic NeoplasmsHumansHistiocytesImmunohistochemistryMutation

Stichwörter der Autor:innen

ALKECDErdheim-Chester diseaseLCHLangerhans cell histiocytosisMAPK/ERKRDDRosai-Dorfman disease

Autor:innen und Institutionen

  • Department of Pathology, Division of Laboratory Medicine-Hematopathology, University of Alabama at Birmingham, Birmingham, AL, US.
  • Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN, US.

ORCID-Profile: Aishwarya Ravindran

Zitieren

APA

Ravindran, A., & Rech, K. L. (2023). How I Diagnose Rosai-Dorfman Disease. American Journal of Clinical Pathology, 160(1), 1-10. https://doi.org/10.1093/ajcp/aqad047

Vancouver

Ravindran A, Rech KL. How I Diagnose Rosai-Dorfman Disease. American Journal of Clinical Pathology. 2023;160(1):1-10. doi:10.1093/ajcp/aqad047

BibTeX
@article{Ravindran2023,
  author = {Ravindran, Aishwarya and Rech, Karen L},
  title = {How I Diagnose Rosai-Dorfman Disease},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  volume = {160},
  number = {1},
  pages = {1--10},
  doi = {10.1093/ajcp/aqad047}
}
Kostenlos starten →